Mon, Jul 14, 2014, 4:58 AM EDT - U.S. Markets open in 4 hrs 32 mins

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • theman111knows theman111knows Nov 26, 2012 6:43 PM Flag

    Burrill Institutional Research "SRPT is an Undervalued Opportunity " Target $ 54

    The Street Insider 11/26
    Burrill Starts Sarepta (SRPT) at Market Outperform; Sees Plenty of Upside in DMD Space
    Burrill Institutional Research started coverage on Sarepta Therapeutics (Nasdaq: SRPT) at Market Outperform establishing a $54 price target in the process.
    Analyst/managing director Reni Benjamin commented, "To date, the company has demonstrated both safety and preliminary efficacy in Phase 1 and Phase 2 trials with patients amenable to Exon 51 therapy in Duchenne’s Muscular Dystrophy (DMD). Given the final encouraging results from the 201/202 Phase 2 study, we believe shares are poised to move higher. If successful, we believe Sarepta’s directed alternative splicing technology has the potential to revitalize the RNA therapeutics space and address multiple multi-billion dollar orphan disease markets. In our opinion, the company represents an undervalued opportunity with multiple near-term drivers poised to create shareholder value in 2013."

 
SRPT
21.98-0.56(-2.48%)Jul 11 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Shire plc
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
Lorillard, Inc.
NYSEFri, Jul 11, 2014 4:01 PM EDT